Related Experiment Video
Updated: Jun 14, 2025
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
A Newly Developed Anti-L1CAM Monoclonal Antibody Targets Small Cell Lung Carcinoma Cells
Miki Yamaguchi1, Sachie Hirai1, Masashi Idogawa2
1Department of Molecular Medicine, Research Institute for Immunology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Abstract:
Few effective treatments are available for small cell lung cancer (SCLC), indicating the need to explore new therapeutic options. Here, we focus on an antibody-drug conjugate (ADC) targeting the L1 cell adhesion molecule (L1CAM). Several publicly available databases reveal that (1) L1CAM is expressed at higher levels in SCLC cell lines and tissues than in those of lung adenocarcinoma and (2) the expression levels of L1CAM are slightly higher in SCLC tissues than in adjacent normal tissues. We conducted a series of in vitro experiments using an anti-L1CAM monoclonal antibody (termed HSL175, developed in-house) and the recombinant protein DT3C, which consists of diphtheria toxin lacking the receptor-binding domain but containing the C1, C2, and C3 domains of streptococcal protein G. Our HSL175-DT3C conjugates theoretically kill cells only when the conjugates are internalized by the target (L1CAM-positive) cells through antigen-antibody interaction. The conjugates (an ADC analog) were effective against two SCLC-N (NEUROD1 dominant) cell lines, Lu-135 and STC-1, resulting in decreased viability. In addition, L1CAM silencing rendered the two cell lines resistant to HSL175-DT3C conjugates. These findings suggest that an ADC consisting of a humanized monoclonal antibody based on HSL175 and a potent anticancer drug would be effective against SCLC-N cells.
Insights
New antibody-drug conjugates targeting L1 cell adhesion molecule (L1CAM) show promise for small cell lung cancer (SCLC). This therapy effectively reduced SCLC-N cell viability in vitro, suggesting a potential new treatment option.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Small cell lung cancer (SCLC) has limited effective treatment options.
- L1 cell adhesion molecule (L1CAM) is upregulated in SCLC compared to lung adenocarcinoma and normal tissues.
- Targeting L1CAM presents a potential therapeutic strategy for SCLC.
Purpose of the Study:
- To evaluate the efficacy of an antibody-drug conjugate (ADC) targeting L1CAM in SCLC.
- To investigate the role of L1CAM expression in SCLC sensitivity to ADC therapy.
Main Methods:
- In vitro experiments using an anti-L1CAM monoclonal antibody (HSL175) conjugated with a diphtheria toxin-based payload (DT3C).
- Assessing the cytotoxic effect of the HSL175-DT3C conjugate on SCLC-N cell lines (Lu-135 and STC-1).
- Evaluating the impact of L1CAM gene silencing on cellular resistance to the ADC.
Main Results:
- The HSL175-DT3C conjugate demonstrated effectiveness in reducing the viability of L1CAM-positive SCLC-N cell lines.
- L1CAM silencing conferred resistance to the HSL175-DT3C conjugate, confirming target specificity.
- The ADC analog showed potent anti-cancer activity against SCLC-N cells in vitro.
Conclusions:
- An ADC targeting L1CAM is a promising therapeutic approach for SCLC, particularly SCLC-N subtypes.
- Further development of L1CAM-targeting ADCs, potentially using humanized antibodies and potent anticancer drugs, is warranted for SCLC treatment.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
